- Details
- At the 2024 LUGPA annual meeting, Scott Eggener reviews cutting-edge prostate cancer technologies, from screening and imaging to genomic testing and emerging treatments. He provides balanced perspectives on new innovations, emphasizing evidence-based adoption and cautioning against unproven expensive technologies. Biographies: Scott Eggener, Professor of Surgery (Urologic Oncology) and Radiology,...
|
- Details
- Oliver Sartor speaks with Russ Pachynski, Chris Maher, and Aadel Chaudhuri about their novel biomarker study in advanced prostate cancer. The discussion centers on their development of a cell-free DNA assay that examines both AR gene and enhancer alterations in mCRPC patients, showing significant prognostic value for treatment outcomes. Dr. Chaudhuri presents their discovery of a stemness signatur...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Bertrand Tombal challenges traditional salvage radiation approaches in high-risk EMBARK patients. Based on trial results showing enzalutamide's survival benefits, he advocates shifting from radiation-first to systemic ARTA treatment, with radiation as a secondary consideration. Biographies: Bertrand Tombal, MD, PhD, Chairman of the...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Daniel Spratt examines systemic therapy in post-operative biochemical recurrence, challenging universal hormone therapy with salvage radiation. He demonstrates varying benefits based on PSA levels and emphasizes treatment personalization using genomic classifiers and MMAI models. Biographies: Daniel Spratt, MD, Chair and Professor...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Derya Tilki leads a panel with Drs Tombal, Spratt, and Alicja Jereczek-Fossa examining salvage radiation timing, EMBARK trial interpretation, and treatment decision factors in biochemically recurrent prostate cancer, balancing PSA levels and patient-specific characteristics. Biographies: Derya Tilki, MD, Associate Professor of Urol...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Paul Nguyen analyzes treatment approaches for post-prostatectomy and salvage radiation biochemical recurrence, comparing SBRT versus whole pelvis radiation for lymph node metastases. He examines current evidence and ongoing trials informing treatment decisions. Biographies: Paul L. Nguyen, MD, MBA, FASTRO, Baldwin-Politi Distinguis...
|
- Details
- Oliver Sartor speaks with Louise Emmett about combination therapy approaches with lutetium-PSMA in prostate cancer. The discussion explores various combination strategies, including promising results from the ENZA-p trial combining lutetium-PSMA with enzalutamide, which shows notable response rates in first-line mCRPC. They examine multiple potential combination approaches, including hormonal ther...
|
- Details
- Phuoc Tran and Tim Showalter join Zachary Klaassen to discuss two presentations examining the ArteraAI prostate test in oligometastatic castration-sensitive prostate cancer. The conversation explores validation studies demonstrating the test's prognostic value for overall survival and its potential to predict benefit from metastasis-directed therapy using data from the STOMP and ORIOLE trials. The...
|
- Details
- Ursula Vogl discusses key prostate cancer highlights from ESMO 2024. The conversation explores three major trials across different disease stages: the PATCH trial evaluating transdermal estradiol versus LHRH analogs in non-metastatic disease, the ARANOTE trial examining darolutamide in metastatic hormone-sensitive prostate cancer, and the PEACE-3 trial investigating radium-223 plus enzalutamide in...
|
- Details
- Cathy Marshall discusses a non-randomized clinical trial evaluating olaparib without androgen deprivation therapy for high-risk biochemically recurrent prostate cancer following prostatectomy. The study shows promising results, particularly for patients with BRCA2 alterations, where all patients demonstrate PSA-50 responses. The conversation explores the trial design, patient outcomes, and safety...
|
